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ABSTRACT
Molecular mechanism of Rapamycin resistance in cancer cells
by
Sohag Chakraborty

Advisor Name: David A. Foster

The mammalian target of rapamycin (mTOR) acts as the central regulator of multiple cellular
processes including cell growth, proliferation, and survival by integrating signals via nutrients,
growth factors, hormones, and energy sensing. In cancer cells, the mTOR pathway is highly
dysregulated providing survival signals to the cells for their uncontrolled growth. Hence, mTOR
has evolved to be a potential therapeutic target for cancer treatment for the past two decades.
Application of micro-molar doses of Rapamycin in vitro has been found to successfully inhibit
mTOR complex 1 (mTORC1) by blocking the phosphorylation of its downstream substrates- a)
ribosomal protein p70 S6 kinase (S6K) and b) eukaryotic initiation factor 4E (eIF4E)-binding
protein 1 (4E-BP1). Previous studies have shown that Rapamycin acts as a cytostatic drug and
causes G1 cell cycle arrest in the presence of transforming growth factor- (TGF-β). However, in
the absence of TGF-β signal, the drug induces cell-death. The rationale behind the cytotoxic effect
of Rapamycin in the absence of TGF-β is that without TGF-β, the cells do not arrest in G1 and
progress into S phase where they lack further survival signals from mTORC1 which has been
inhibited by Rapamycin – therefore, the cells undergo apoptosis. Of significance, we have found
that cancer cells with mutated RB and CDKN2A are not susceptible to cell-death upon Rapamycin
treatment in the absence of TGF-β. The gene products of RB and CDKN2A (pRb and p14ARF
respectively) suppress E2F family transcription factors that promote cell cycle progression from
iv

G1 into S. Restoration of wild type RB or inhibition of E2F activity in cancer cells led to
Rapamycin sensitivity. These data provide evidence that the combination of mutant RB and
mutant CDKN2A in cancer cells leads to Rapamycin resistance, which has implications for
precision medicine approaches to anti-cancer therapies.

v

ACKNOWLEDGEMENTS

I would like to express my sincere gratitude to my thesis advisor and mentor Dr. David
Foster for giving me the opportunity to work in his lab, and his encouragement throughout this
journey. Specially during the pandemic, his support, motivation, and patience is greatly
appreciable. He has always ignited me to think critically, fostered my scientific acumen, allowed
intellectual freedom, and taught me to keep an open-minded attitude for novel ideas. I could not
have imagined having a better advisor for my Ph.D. study.
Besides my advisor, I would also like to thank the rest of my committee members: Dr. Jill
Bargonetti, Dr. Patricia Rockwell, Dr. Amy Ikui and Dr. Poulikos Poulikakos for their insightful
comments, valuable ideas, and encouragement. I am especially thankful to them for investing their
valuable time to join my committee meetings, read my work, and providing critical feedback.
I would like to thank Dr. Richard Magliozzo, Judy Li, Dr. Sebastien Poget and Denise
Charles from the Biochemistry Program at the Graduate Center, CUNY for their immense help
and support throughout my PhD course. I truly appreciate their assistance during my initial struggle
period as an international student and also with my defense meeting arrangements and other
official requirements. I also want to thank all the mentors and researchers at the Belfer Research
Building and Biology Department of the Hunter College, CUNY for providing such an
enthusiastic, interdisciplinary, and interactive working environment for research.
A huge thank you to all the former and present lab members from the Foster lab: Deepak
Menon, Deven Patel, Matthew Utter, Elyssa Bernfeld, Limor Goren, Maria Frias, Sharmeen
Uddin, Ahmet Hatipoglu and Sweetha Selvarajan. All of them have made my Ph.D. journey less
stressful and more enjoyable through stimulating discussions during lunch hours and fun activities
vi

both in and outside lab. The diverse culture of our lab has helped me to evolve as a better person
both professionally and personally. Here, I especially want to thank Matthew Utter, with whom I
started working on his project when I joined the lab. He has been my mentor in true sense as he
taught me most of the laboratory techniques, helped me to troubleshoot experiments, and guided
me to improve my data analysis and presentation skills. Thank you to my undergraduate assistants
Bisma Ahmed, Joyessa Dey and Zuha Mohiuddin for their time and contributions towards my
research work.
I would like to thank my family, friends, and relatives who have given sanity to my life
outside the laboratory. I am thankful to my parents Ruma Chakraborty and Samir Chakraborty
who have believed in my potential and motivated me throughout my time of failures and doubts.
Their consistent support from thousands of miles away have enabled me to achieve this milestone.
Thanks to my husband Sayan Chakraborty for persistently boosting me up and believing in me in
everything I have decided to do.
I want to dedicate this work to my paternal grandfather, Late Sudhindranath Chakraborty
whom I lost during childhood, and my maternal grandmother, Late Gita Mukherjee who died of
cancer. My encounter with the disease at a very young age motivated me to pursue research in
cancer biology. Their memories and blessings inspire me to delve more into the enigma of this
disease so I can contribute as little as possible towards improving the treatment for cancer.

vii

CONTENTS
Abstract………………………………………………………………………………… iv
Acknowledgements……………………………………………………………………. vi
List of Figures………………………………………………………………………….ix
List of Tables…………………………………………………………………………...x
List of Abbreviations…………………………………………………………………..xi
Chapter 1: Introduction…………………………………………………………………1
Cell cycle and its key regulators………………………..………………………….2
Differential effects of Rapamycin ………………………………………………....4
mTOR complexes………………………………………………………………….7
Rational……………………………………………………………………………11
Chapter 2: Results……………………………………………………………………...14
Differential Rapamycin sensitivity of cancer cell lines with and without
wild type RB………………………………………………………………………. 15
Rapamycin resistance in cancer cells also requires defective CDKN2A…………...17
Knockdown of pRb in Rapamycin-sensitive cell lines promotes
Rapamycin resistance………………………………………………………………21
Restoration of functional pRb in Rapamycin resistant cells leads to
Rapamycin sensitivity……………………………………………………………...22
Chapter 3: Discussion…………………………………………………………………..24
Chapter 4: Conclusion and Future Directions………………………………………….28
Chapter 5: Materials and Methods……………………………………………………..31
Bibliography…………………………………………………………………………....35
viii

LIST OF FIGURES
Fig. 1.1 Cyclin-CDK regulation of the mammalian cell cycle ………………………………...3
Fig. 1.2 Differential effects of Rapamycin before and after the mTORC1/Cyclin E-CDK2
checkpoint………………………………………………………………………………7
Fig. 1.3 Schematic diagram of mTOR complexes……………………………………………...8
Fig. 1.4 Cell cycle regulation by pRb and E2F ………………………………………………..10
Fig. 1.5 In MDA-MB-231 cells, TGF-β 1 inhibits the apoptotic effect of Rapamycin………..11
Fig. 1.6 Loss of both TGF-β and pRb makes cells resistant to Rapamycin-mediated
cell death…………………………………………………………………………………13
Fig. 2.1 Differential Rapamycin sensitivity of cancer cell lines with and without
wild type pRb…………………………………………………………………………...16
Fig. 2.2 Rapamycin resistance in cancer cells also requires deletion of CDKN2A…………...17
Fig. 2.3 E2F regulation by p16INK4A and p14ARF………………………………………………19
Fig. 2.4 Inhibition of E2F activity sensitizes DU145 and NCI- H2228 cells to
Rapamycin treatment………………………………………………………………....20
Fig. 2.5 Knockdown of pRb in Rapamycin sensitive cell lines leads to
Rapamycin resistance………………………………………………………………..21
Fig. 2.6 Restoration of wild type pRb in Rapamycin resistant cells leads to
Rapamycin sensitivity………………………………………………………………..22

ix

LIST OF TABLES
Table 1.1 RB and CDKN2A mutations correlate with Rapamycin lethality…………….18

x

LIST OF ABBREVIATIONS
4E-BP1- eukaryotic initiation factor 4E (eIF4E) - binding protein 1
ARF- alternating reading frame
CDK- cyclin-dependent kinase
Cl PARP- cleaved PARP
E2F- eukaryotic transcription factor
FACS- fluorescence-activated cell sorting
INK4A- inhibitory-cyclin-dependent kinase protein 4A
mTOR- mammalian Target of Rapamycin
mTORC1- mTOR complex 1
mTORC2- mTOR complex 2
PA- Phosphatidic acid
PARP- poly ADP ribose polymerase
PLD- Phospholipase D
pRb - Retinoblastoma protein
RB- Retinoblastoma gene
Ser- Serine
S6K- ribosomal protein S6 kinase
siRNA- small interference RNA
TOR-Target of Rapamycin
TGF-β- Transforming-growth-factor- β

xi

CHAPTER ONE: INTRODUCTION

1

Cell-cycle and its key regulators
Cell cycle is an organized, highly regulated, and complicated process involving cell
growth and cell division. Sequential and successful passage through Gap 1 (G1), DNA synthesis
(S), Gap 2 (G2) and Mitosis (M) phases of the cell cycle is meticulously controlled by several
checkpoints for precise genome replication and accurate segregation of the replicated
chromosomes into the daughter cells (Schafer, 1998). The cell cycle checkpoints include the
growth-factor mediated restriction checkpoint in G1, DNA damage checkpoint in S and G2 and the
spindle assembly checkpoint in M (Schafer, 1998). The key regulators of these checkpoints that
drive cell cycle progression in mammalian cells are called cyclin-dependent kinases (CDKs) which
become active upon binding with their partners called cyclins. For example, CDK4 and CDK6 are
activated upon binding with cyclin D and these complexes are important for progression of cells
in G1 (Matsushime et al., 1992; Meyerson and Harlow, 1994) whereas, cyclin E-CDK2 complex
is required for progression from G1 to S phase (Endicott et al., 1999; Ohtsubo et al., 1995) (Fig.
1.1). While Cyclin A-CDK2 complex is required for S phase progression, cyclin A-CDK1 complex
is crucial during transition from S to G2 (Pagano et al., 1992; Yam et al., 2002) (Fig. 1.1). Finally,
progression of cells through M is controlled by cyclin B-CDK1 (Gavet and Pines, 2010) (Fig. 1.1).
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Figure 1.1: Cyclin-CDK regulation of the mammalian cell cycle. The cell cycle consists of two
gap (G1 and G2) phases, a DNA synthesis (S) phase and a mitotic (M) phase. In mammalian
cells different cyclin-CDK complexes regulate progression of cells through the different phases
of the cell cycle (Suryadinata et al., 2010).

G1 phase of the cell cycle, where the cells grow in size and prepare themselves for DNA
synthesis, can be divided into “Early and Late G1” by a mid G1 site known as the Restriction point
(R) (Pardee, 1974; 2002; Zetterberg et al., 1995). At R, the cells determine whether DNA
replication should take place in the S phase depending on the presence of extracellular stimuli such
as growth-factors and the regulation of cyclin D-CDK4/6 complexes. In the absence of growth
factors, the cells exit the cell cycle and enter the quiescence state known as G0. Between R and the
initiation of S phase, there are a series of metabolic checkpoints that monitor the levels of essential
amino acids, the “conditionally” essential amino acid i.e. glutamine (Saqcena et al., 2013), and
lipids (Patel et al., 2017). Passage of cells through the late G1 into S is controlled by the mammalian
3

Target of Rapamycin Complex 1 (mTORC1), transforming growth-factor- (TGF-β), and cyclin
E-CDK2 complex (Fig. 1.2). This site, which has also been referred to as R (Planas-Silva and
Weinberg, 1997), is likely the final arbiter for proceeding to S phase and committing to replicate
the genome. Thus, passage through mid G1 is dependent on cyclin D-CDK4/6 complexes and
growth-factor signals indicating that it is appropriate to divide, whereas passage through the late
G1- mTORC1 checkpoint is determined whether there is sufficient nutrients for the cells to double
their mass and divide (Foster et al., 2010). We have referred to the mid G1-growth-factordependent checkpoint and the late G1-mTORC1 dependent checkpoint as R1 and R2 respectively
(Patel et al., 2017) (Figure 1.2). The most dysregulated signals that stimulate cell proliferation and
promote survival in human cancer cells are the results of mutations in genes that regulate G1 to S
progression (Foster et al., 2010; Ho and Dowdy, 2002; Sherr, 2000).
Differential effects of Rapamycin
Rapamycin was first extracted from the bacterial species Streptomyces hygroscopicus,
found in a soil sample collected from the island of Rapa Nui (Sehgal et al., 1975). The compound
was primarily discovered as a macrolide that was found to possess immunosuppressive and antiproliferative properties when applied to mammalian cells (Eng et al., 1984; Martel et al., 1977).
Surprisingly, after two decades of this discovery, the target protein of Rapamycin, a
serine/threonine protein kinase complex called TOR (Target of Rapamycin) was initially
detected in yeast, followed by the discovery of a homologous protein in mammalian cells called
mammalian Target of Rapamycin (mTOR) (Heitman et al., 1991; Kunz et al., 1993; Sabatini et
al., 1994; Sabers et al., 1995).
4

Rapamycin forms a complex with the immunophilin FK506 binding protein 12
(FKBP12) which allosterically inhibits mTOR (Sabers et al., 1995; Yip et al., 2010). The
complex binds at the FKBP12-Rapamycin binding (FRB) domain of mTOR through competitive
inhibition where Rapamycin competes with phosphatidic acid (PA) for the same binding site and
prevents the interaction of mTOR with PA (Fang et al., 2001; Toschi et al., 2009). PA is crucial
for mTOR activation and is produced from phosphatidylcholine by the catalytic action of
phospholipase D (PLD) enzyme (Exton, 2002).
Different concentrations of Rapamycin are used to inhibit mTOR under distinct
circumstances. At nano-molar (nM) dose, Rapamycin has been shown to partially inhibit
mTORC1 activity by suppressing the phosphorylation of p70 S6K (Fingar et al., 2002; Foster
and Toschi, 2009; Yellen et al., 2011). Such low dose treatment causes partial G1 cell cycle arrest
in cancer cells (Choo et al., 2008; Yellen et al., 2011). In contrast, micro-molar (µM) doses of
Rapamycin fully inhibit mTORC1 by suppressing the phosphorylation of both S6K and 4E-BP1
– and causing complete G1 cell cycle arrest (Yellen et al., 2011). Since Rapamycin-FKBP12
complex binding is mTORC1 specific, initial studies suggested that only mTORC1 is inhibited
by Rapamycin and mTORC2 is insensitive to Rapamycin inhibition (Sabers et al., 1995).
However, further investigation revealed that prolonged treatment with Rapamycin negatively
affects mTORC2 assembly, where Rapamycin binds to free mTOR molecule and inhibits its
activity (Sarbassov et al., 2006). In addition, previous studies from our lab demonstrated that
with low PA concentrations, 200 nm Rapamycin treatment for 6 hours could inhibit mTORC2
via dissociation of mTOR and Rictor and suppress AKT phosphorylation (Toschi et al., 2009).
5

Rapamycin, at M dose, that inhibit 4E-BP1 phosphorylation (Yellen et al., 2011)
causes cell cycle arrest in late G1 and is dependent on both TGF- and the suppression of 4EBP1 phosphorylation (Chatterjee et al., 2015). While Rapamycin induces cell cycle arrest in late
G1, the effect is dependent on TGF-β, whereas in the absence of TGF-β (present in serum), cells
progress into S phase where Rapamycin causes apoptosis instead of cell cycle arrest (Gadir et
al., 2008; Gan et al., 2015; Saqcena et al., 2015). If cells are arrested after the late G1 - TGF-βdependent mTORC1 checkpoint (R2), Rapamycin induces apoptosis even in the presence of
serum/TGF-β (Gadir et al., 2008). This is shown schematically in Fig. 1.2 where we speculate
that cells arrested by Rapamycin before the TGF-β dependent mTORC1 checkpoint, but if
Rapamycin is added after this checkpoint, the cells enter S phase where the drug induces
apoptosis rather than cell cycle arrest (Gadir et al., 2008; Saqcena et al., 2015).
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Figure 1.2: Differential effects of Rapamycin before and after the mTORC1/Cyclin E-CDK2
checkpoint. Two major G1 cell cycle checkpoints, R1 and R2, are defined by their dependence on
cyclin D-CDK 4/6 and cyclin E-CDK2 complexes, respectively. In the presence of TGF-β,
Rapamycin treatment induces G1 cell cycle arrest at the late G1 mTORC1-dependent cyclin E
checkpoint – R2 (Foster et al., 2010; Patel et al., 2017). However, if cells progress past R2, they
undergo apoptosis in response to Rapamycin. Inhibition of mTORC1 with Rapamycin potentiates
TGF- signals (Chatterjee et al., 2015), leading to elevated levels of the cyclin E-CDK2 inhibitors
p21 and p27 (Ciarallo et al., 2002; Gong et al., 2003). Thus, inhibition of mTORC1 signals by
Rapamycin leads to elevated TGF-β signals and the inhibition of cyclin E-CDK2 signals – causing
cell cycle arrest at R2. If TGF-β signaling is compromised, then cells are not arrested in late G1
by Rapamycin, and they progress into S phase where mTORC1, an indicator of nutritional
sufficiency, is required. The lack of mTORC1 signals activates a default apoptotic program that
prevents cell cycle progression in what is perceived as the absence of nutrients needed for
replicating the genome and cytokinesis (Foster et al., 2010; Saqcena et al., 2015).

mTOR complexes
mTOR, a serine/threonine kinase protein, forms the catalytic subunit of two different
protein complexes, mTORC1 and mTORC2. The core components of mTORC1 includes mTOR,
regulatory associated protein of mTOR (Raptor), mammalian lethal with Sec13 protein 8
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(mLST8), proline-rich AKT substrate 40 kDa (PRAS40), and DEP domain-containing mTOR
interacting protein (Deptor) (Hara et al., 2002; Jacinto et al., 2004; Kim et al., 2002; Kim et al.,
2003; Peterson et al., 2009; Sancak et al., 2007) (Fig. 1.3). All these protein components engage
in regulating mTOR assembly, localization, activation, and substrate recognition. Upon
stimulation by upstream signals such as nutrients (amino acids, glucose), oxygen levels, and
growth factors, mTORC1 phosphorylates its downstream substrates S6K and 4E-BP1.
Phosphorylation by mTOR activates S6K, which in turn phosphorylates its target, S6 ribosomal
protein leading to protein synthesis required for cellular growth and proliferation (Brown et al.,
1995). In contrast, phosphorylation of 4E-BP1 inhibits its action resulting in activation of eIF4E
and enhancing mRNA translation (Hara et al., 1997).

Figure 1.3: Schematic diagram of mTOR complexes. In mTORC1, mTOR interacts with Raptor,
mLST8, PRAS40 and Deptor. The two most recognized downstream targets of mTORC1 are S6K
and 4E-BP1. In mTORC2, mTOR interacts with Rictor, mLST8, mSIN1, Protor 1/2 and Deptor.
mTORC2 function by regulating its downstream target AKT.
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mTORC2 is comprised of mTOR, Rapamycin-insensitive companion of mTOR (Rictor),
mLST8, Deptor, MAPK interacting protein 1 (mSIN1) and protein associated with Rictor 1/2
(Protor 1/2) (Frias et al., 2006; Jacinto et al., 2006; Kim et al., 2003; Pearce et al., 2007; Pearce et
al., 2011; Peterson et al., 2009; Sarbassov et al., 2004) (Fig. 1.3). Upon activation by growth
factors such as insulin, mTORC2 phosphorylates its main downstream target AKT leading to
cytoskeletal organization and cell survival (Sarbassov et al., 2005).
In approximately 80% of human cancers, mTOR signaling is hyperactive (Saxton and
Sabatini, 2017). Upregulation of mTOR causes deactivation of most tumor suppressor proteins
and cellular processes that control abnormal proliferation (Saxton and Sabatini, 2017). Hence,
mTOR plays a critical role in promoting cancer cell growth and survival.
The TGF-β signaling pathway is one of the best characterized pathways involved in cell
cycle regulation – causing G1 arrest (Siegel and Massague, 2003). The nuclear signal by which
TGF-β induces its growth inhibitory effect includes two major mechanisms – 1) suppression of
cyclin and cyclin dependent kinase (CDK) complexes (Ciarallo et al., 2002; Gong et al., 2003)
and 2) activation of the tumor suppressor protein Retinoblastoma (pRb) by inhibiting its
phosphorylation (Laiho et al., 1990). TGF-β activation leads to accumulation of two cyclin
dependent kinase inhibitor (CKI) proteins – p27Kip1 and p21Cip1 (Ciarallo et al., 2002; Gong et al.,
2003). p27 inhibits the activity of cyclin E-CDK2 complex alone, while p21 is associated with
inactivating both cyclin D-CDK4 and cyclin E-CDK2 complexes (Koff et al., 1993; Shi and
Massague, 2003) (Fig.1.2). Cyclin D-CDK4/6 and cyclin E-CDK2 complexes are known to hypo-
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phosphorylate and hyper-phosphorylate pRb respectively all along G1 phase of the cell cycle
preventing cell cycle arrest (Malumbres, 2014)

Figure 1.4: Cell cycle regulation by pRb and
E2F. pRb in its unphosphorylated state binds
to E2F blocking S phase progression. Cyclin
D-CDK4/6 complex hypo-phosphorylates
and Cyclin E-CDK2 complex hyperphosphorylates pRb causing dissociation of
E2F from pRb leading to G1 to S phase
progression.

pRb was discovered as the first tumor suppressor protein and is widely found in
quiescent cells during G1 cell cycle phase and was found to arrest cells during check point
mediated transition from G1 to S phase (Dyson, 2016). Unphosphorylated pRb binds to the
eukaryotic transcription factor E2F and interacts with other chromatin regulators and inhibits
transcription of E2F target genes (Weinberg, 1995). Hence, pRb restricts expression of cell cycle
genes required for cell proliferation. However, hyper-phosphorylated pRb dissociates from E2F
and free E2F facilitates cell cycle progression (Weinberg, 1995) (Fig. 1.4).
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Rationale
Early studies from our lab suggests that while Rapamycin causes full G1 arrest in cancer
cells in serum-supplemented media, cells treated with the same dose of Rapamycin undergo
apoptosis in the absence of serum (Gadir et al., 2008). As shown in Fig.1.5a (Gadir et al., 2008),
cells grown in serum-supplemented as well as serum-free media without Rapamycin, had high
DNA content in G1 phase indicating more viable cells in G1 phase as compared to other phases.
Similar results were found with cells treated with Rapamycin in the presence of serum indicating
that cells are arrested in G1 phase. On the contrary, cells treated with Rapamycin in serum-free
media had sub-genomic DNA content suggesting significant cell death (Fig. 1.5a) (Gadir et al.,
2008). These findings led to the question – Is there a factor (or factors) present in the serum which
is triggering this switch between the cytostatic and cytotoxic effects of Rapamycin?

Figure 1.5: In MDA-MB-231 cells, TGF-β 1 inhibits the apoptotic effect of Rapamycin (Gadir
et al., 2008). (a) Flow cytometric analysis showing the DNA content in different phases of the cell
cycle per cell graphically. The percentage of cells in G1 phase under different conditions are
serum- media - 56%, serum-media + Rapa 67%; serum-free media - 60% and serum-free media
+ Rapa - < 1%. (b) Flow cytometric analysis showing the significant increase in the DNA content
with addition of TGF-β in serum-free media even in presence Rapamycin (Gadir et al., 2008).
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Further investigation revealed this factor to be TGF-β which is regulating the effect of Rapamycin
treatment on cancer cells (Gadir et al., 2008). In the absence of TGF-β or serum (in which TGF-β
is present), Rapamycin was causing cell-death (Fig. 1.5b) whereas addition of TGF-β in serumfree media was found to induce G1 cell cycle arrest upon Rapamycin treatment instead of celldeath (Fig. 1.5b) (Gadir et al., 2008).
The most well-known activation process of TGF-β signaling involves phosphorylation of
the intracellular regulatory SMAD proteins- SMAD2 and SMAD3 which subsequently form
complex with a co-SMAD, SMAD4 (Shi and Massague, 2003). The SMAD protein complex is
thereby translocated into the nucleus where transcription of different effector proteins is induced
(Shi and Massague, 2003).
Previous investigations have shown that in a wide variety of cancer types, TGF-β
signaling is dysfunctional due to loss-of-function mutation of SMAD4 protein which promotes
cell growth and proliferation facilitating tumorigenesis (Principe et al., 2016; Yang, 2010). To
mimic the loss of TGF-β signals and test the effect of Rapamycin in cancer cells, our lab
demonstrated that when SMAD4 was knocked down in MDA-MB-231 cell line, the cells were
undergoing apoptosis upon Rapamycin treatment in the presence of serum (Chatterjee et al., 2015)
(Fig. 1.6). Surprisingly, when pRb was knocked down simultaneously with SMAD4, the cells
became resistant to Rapamycin-induced apoptosis (Chatterjee et al., 2015) (Fig. 1.6).
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Figure 1.6: Rapamycin employs TGF-β and pRb pathway to cause cell cycle arrest (Chatterjee
et al., 2015). MDA-MB-231 cells were plated at a density of 300,000 in a 6 well plate in media
with 10% serum overnight. The cells were transfected with negative control siRNA, siRNA for
SMAD4 or pRb or both as indicated. 24 h after transfection, cells were treated with 20 M
Rapamycin as indicated. After another 18h, the levels of Cl PARP, SMAD4, pRb and Actin were
determined by Western Blot analysis. The data is a representation of at least two independent
experiments (Chatterjee et al., 2015).

These data suggest that knock down of pRb expression can suppress the apoptotic effects
of high dose Rapamycin in MDA-MB-231 cells. In this thesis, we examine the effect Rapamycin
on cancer cells with RB mutations.
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CHAPTER TWO: RESULTS
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Differential Rapamycin sensitivity of cancer cell lines with and without wild type RB
We reported previously that high dose Rapamycin (20μM) has a cytotoxic effect on
cancer cell lines in the absence of TGF-β signals (Gadir et al., 2008). When TGF-β signaling is
blocked, cells are free to progress through a late G1 cell cycle checkpoint into S-phase where
suppression of mTORC1 induces apoptosis instead of cell cycle arrest (Saqcena et al., 2015). In
the absence of serum/TGF-β, MDA-MB-231 and MCF-7 breast cancer cells were killed by
treatment with 20M Rapamycin as determined by uptake of trypan blue (Fig. 2.1A). We also
observed cleavage of the caspase 3 substrate PARP – indicating apoptotic cell death (Fig. 2.1A).
In contrast, DU145 prostate and NCI-H2228 lung cancer cells were not killed by Rapamycin in
the absence of serum/TGF-β (Fig. 2.1A). A striking difference between the cancer cell lines was
mutated RB in the DU145 (Itoh et al., 1997) and NCI-H2228 (Tam et al., 2013) cells, but not in
the MDA-MB-231 and MCF-7 cells (Yoshida et al., 2010). We also examined cell viability using
the XTT assay that measures metabolic activity in viable cells (Roehm et al., 1991). As shown in
Fig. 2.1B, Rapamycin suppressed metabolic activity in the MDA-MB-231 and MCF-7 cells when
deprived of serum/TGF-β as described previously (Gadir et al., 2008). In contrast, the DU145 and
NCI-H2228 cells survived Rapamycin treatment in the absence of serum. These data suggest that
the difference in Rapamycin sensitivity in these cells is due to the lack of wild type RB in the
DU145 and NCI-H2228 cells.
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A

B

Figure 2.1: Differential Rapamycin sensitivity of cancer cell lines with and without wild type
pRb. (A) MDA-MB-231, MCF-7, NCI-H2228 and DU145 cells were plated at a density of 200,000
cells/well in 6-well plates in complete media containing 10% serum. Cells were then treated with
20µM Rapamycin or DMSO in media with no serum as indicated. After 24 h, cells were harvested,
and cell viability was measured through trypan blue exclusion assay as described in Materials and
Methods. Cell lysates were used to probe for Cl PARP, an indicator of early apoptosis and Actin
by Immunoblot analysis. (B) The indicated cell lines were treated with 20µM Rapamycin or DMSO
in complete media or serum deprived media as indicated. After 24 h, cell viability was measured
via the reduction of XTT. All experiments were performed in triplicates. Error bars represent +
SEM. Unpaired Student’s t test was performed using GraphPad Prism 8 software. ns means not
significant (p > 0.05); **, p < 0.01; ***, p < 0.00.
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Rapamycin resistance in cancer cells also requires defective CDKN2A
We extended the study to other cell lines with reported RB mutations – MDA-MB-468
and BT-549 breast cancer cells (Ikediobi et al., 2006; Yoshida et al., 2010). The MDA-MB-468
and BT-549 cells were subjected to XTT cell viability assay used in Fig. 2.1B. Surprisingly, these
cells displayed a sensitivity to Rapamycin in the absence of serum (Fig. 2.2) similar to that
observed for MDA-MB-231 and MCF-7 cells in Fig. 2.1. Consistent with the loss of cell viability
observed with Rapamycin treatment in the absence of serum, there was also a substantial increase
in cleaved PARP (Fig. 2.2), indicating apoptotic cell death. These data indicated that there was
more to the Rapamycin resistance in cancer cells than loss of wild type RB.
Figure 2.2: Rapamycin resistance in
cancer cells also requires deletion of
CDKN2A. MDA-MB-468 and BT-549
cells were plated at a density of 200,000
cells/well in 6-well plates in complete
media containing 10% serum overnight.
Cells were then treated with 20µM
Rapamycin or DMSO in serum deprived
media as indicated. After 24 h, cell lysates
were collected and used to probe for Cl
PARP, phospho-4E-BP1 (Ser65), total
4E-BP1 and GAPDH by Immunoblot
analysis. For cell viability assay, the same
cell lines were treated with 20µM
Rapamycin or DMSO in serum deprived
media as indicated. After 24 h, cell
viability was measured via the reduction
of XTT. All experiments were performed
in triplicates. Error bars represent +
SEM. Unpaired Student’s t test was
performed using GraphPad Prism 8
software (**, p < 0.01; ****, p < 0.0001).
A potentially important difference between the Rapamycin resistant DU145 and NCIH2228 cells and the Rapamycin sensitive MDA-MB-468 and BT-549 cells is that the DU145 and
NCI-H2228 cells have CDKN2A mutations whereas MDA-MB-468 and BT-549 cells have wild
17

type CDKN2A (Table 1). A pattern can be seen whereby wild type genes for either RB or
CDKN2A correlates with sensitivity to the apoptotic effects of Rapamycin, whereas mutations in
both the genes correlates with Rapamycin resistance.
Table 1: RB and CDKN2A mutations correlate with Rapamycin lethality. Cell lines with both
mutated RB and CDKN2A are resistant to the apoptotic effects of Rapamycin but can be sensitized
to Rapamycin with the reintroduction of wild type RB (DU145 and NCI-H2228). Cell lines with
wild type RB and deleted CDKN2A are not resistant to the effects of Rapamycin but can be made
so by the knock-down of RB expression (MDA-MB-231 and MCF-7). Cell lines with mutated RB
and wild type CDKN2A are not resistant to Rapamycin induced apoptosis (MDA-MB-468 and BT549). “c” = cDNA reference sequence; “fs” = frameshift mutation.

CDKN2A is a gene that produces two distinct proteins, p16INK4A and p14ARF that are
translated from alternative reading frames (Alhejaily et al., 2014; Zhao et al., 2016). p16INK4A is a
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kinase inhibitor which suppresses the phosphorylation of pRb by cyclin D-cyclin-dependent kinase
4/6 (CDK 4/6) complex (Witkiewicz et al., 2011) (Fig. 2.3). Hence, unphosphorylated pRb can
bind to E2F causing G1 arrest (Fig. 2.3). Therefore, loss of p16INK4A is somewhat redundant with
mutated pRb or loss of pRb– in that phosphorylated pRb is similar to not having wild type pRb –
since E2F is liberated in both situations (Witkiewicz et al., 2011).
While p14ARF is known for preventing the
degradation of p53 mediated by MDM2 (Agrawal
et al., 2006), a lesser-known function of p14ARF is
the binding to E2F and suppression of E2F
mediated transcription (Mason et al., 2002) (Fig.
2.3).
Figure 2.3: E2F regulation by p16INK4A and
p14ARF. CDKN2A gene encodes for two kinase
inhibitor proteins, p16INK4A and p14ARF. p16INK4A
suppresses the phosphorylation of pRb by cyclin
D-CDK 4/6 complex. pRb, in its unphosphorylated
state binds to E2F blocking S-phase progression.
Whereas p14ARF binds to E2F directly and
suppresses E2F mediated transcription of genes
required for cell cycle progression.

Thus, the most important outcome of CDKN2A loss with regards to Rapamycin resistance
could be the loss of p14ARF, which would prevent inhibition of E2F-mediated transcription. To test
this hypothesis, we used HLM006474 – a pan E2F inhibitor that inhibits the transcriptional activity
of E2F (Ma et al., 2008). When E2F transcriptional activity was inhibited by HLM006474 in
DU145 and NCI-H2228 cells and treated with Rapamycin, there was a substantial increase in
cleaved PARP when the cells were treated with both Rapamycin and HLM006474 (Fig. 2.4). Since
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HLM006474 inhibits E2F, it is mimicking p14ARF activity and therefore restores a component of
CDKN2A – and in doing so restores apoptotic response to Rapamycin. The DU145 and NCI-H2228
cells were also subjected to the XTT assay which indicated a reduction in the number of viable
cells with combined treatment with the E2F inhibitor and Rapamycin (Fig. 2.4). Thus, inhibition
of E2F activity was able to restore sensitivity to Rapamycin treatment in DU145 and NCI-H2228
cells – consistent with the hypothesis that both RB and CDKN2A need to be mutated to cause
Rapamycin resistance.

Figure 2.4: Inhibition of E2F activity sensitizes DU145 and NCI- H2228 cells to Rapamycin
treatment. DU145 and NCI- H2228 cells were plated as in Fig. 2.2 and then treated with 20µM
Rapamycin or DMSO and 40µM HLM006474 for 18 h, as indicated in serum derived media.
Expression levels of Cl PARP, phospho-4E-BP1 (Ser65), total 4E-BP1 and GAPDH were
determined by Immunoblot analysis. For cell viability assay, the indicated cell lines were treated
with 20µM Rapamycin or DMSO in serum deprived media as indicated. After 24 h, cell viability
was measured via the reduction of XTT. All experiments were performed in triplicates. Error bars
represent + SEM. Unpaired Student’s t test was performed using GraphPad Prism 8 software (*,
p < 0.05;).
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Knockdown of pRb in Rapamycin-sensitive cell lines promotes Rapamycin resistance
The data in Fig. 2.1 revealed a correlation between the presence of wild type pRb and
sensitivity to the apoptotic effects of Rapamycin. We, therefore, examined the effect of pRb
knockdown on Rapamycin sensitivity in the Rapamycin-sensitive MDA-MB-231 and MCF-7 cells
– both of which have mutations in CDKN2A (Table 1). As shown in Fig 2.5, when the pRb levels
were knocked down in MDA-MB-231 and MCF-7 cell lines, the cells displayed resistance to the
cytotoxic effects of Rapamycin as indicated by the reduction of cleaved PARP levels. We
measured Rapamycin efficacy through phosphorylation of 4E-BP1 since our lab had previously
shown that the apoptotic effects of Rapamycin necessitated high doses that inhibit phosphorylation
of 4E-BP1 by mTORC1 (Yellen et al., 2011). The data presented in Fig. 2.5 indicate that the loss
of pRb can contribute to Rapamycin resistance in CDKN2A mutant cancer cells.
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Figure 2.5: Knockdown of pRb in Rapamycin sensitive cell lines leads to Rapamycin resistance.
MDA-MB-231 and MCF-7 cells were plated as in Fig. 2.2. Cells were transfected with negative
control siRNA or siRNA for pRb as indicated. Cells were treated with 20µM Rapamycin or DMSO
in serum deprived media for 18 h, as indicated and 72 h after transfection, cells were harvested
and levels of Cl PARP, pRb, phospho-4-EBP1 (Ser65), total 4E-BP1 and Actin were determined
by Immunoblot analysis. The data is a representation of at least three independent trials.
Restoration of functional pRb in Rapamycin resistant cells leads to Rapamycin sensitivity
We were curious to know whether expression of wild type pRb in Rapamycin resistant
mutant pRb cancer cells can restore Rapamycin sensitivity. A plasmid vector expressing wild type
pRb was transfected into DU145 and NCI-H2228 cells and the cell lysates showed an increase in
cleaved PARP levels when treated with Rapamycin in the absence of serum (Fig. 2.6). This
indicated that the Rapamycin resistant cells with restored pRb expression were undergoing
apoptotic cell death with Rapamycin treatment and further reinforced the premise that wild type
pRb is required for the cytotoxic effects of Rapamycin in cancer cells.

Figure 2.6: Restoration of wild type pRb in Rapamycin resistant cells leads to Rapamycin
sensitivity. DU145 and NCI-H2228 cells were plated as in Fig. 2.2. Cells were transfected with
22

empty vector (EV) or a plasmid expressing HA-tagged pRb as indicated. Cells were treated with
20µM Rapamycin or DMSO in serum deprived media for 18 h and 48 h after transfection, cells
were harvested and levels of Cl PARP, pRb, phospho-4E-BP1, total 4E-BP1 and actin were
determined by immunoblot analysis. The data is a representation of at least three independent
trials.
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CHAPTER THREE: DISCUSSION
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In this report we have identified a genetic profile that confers resistance to the
apoptotic effects of Rapamycin. Previous work from our lab showed that Rapamycin, at doses
capable of suppressing 4E-BP1 phosphorylation (Yellen et al., 2011), induces G1 cell cycle arrest
in the presence of TGF-β; however, in the absence of TGF-β, cancer cells progressed into Sphase where Rapamycin induces apoptosis (Gadir et al., 2008; Le Gendre et al., 2013; Saqcena
et al., 2015). This effect was observed in a variety of cancer cells, however, we found that
Rapamycin did not kill cancer cells with mutated RB and CDKN2A. Both RB and CDKN2A genes
contribute to the regulation of E2F family transcription factors (Kent and Leone, 2019; Mason
et al., 2002; Rubin et al., 2020). Consistent with a role for the RB and CDKN2A genes in
promoting resistance to the apoptotic effects of Rapamycin, inhibition of E2F led to a robust
induction of apoptosis in the presence of Rapamycin (Fig. 2.4). If pRb expression is knocked
down in MDA-MB-231 and MCF-7 cells, which already have a CDKN2A mutation (Ikediobi et
al., 2006), E2F levels were elevated, and Rapamycin did not induce apoptosis (Fig. 2.5). If wild
type pRb expression is restored in DU145 and NCI-H2228 cells, Rapamycin now induces
apoptosis (Fig. 2.6). Collectively, the data support a model whereby mutations in RB and
CDKN2A lead to elevated levels of E2F family transcription factors that suppress apoptosis
induced by high doses of Rapamycin.
mTORC1 has been referred to as an integrator of nutrient and growth factor signals
(Efeyan et al., 2015; Fingar and Blenis, 2004) and may be the final checkpoint prior to entering
S-phase (Saqcena et al., 2013). If cells manage to get past the mTORC1-cyclin E-dependent R2
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checkpoint in late G1 (Fig. 1.2), the cells believe that there are sufficient nutrients and growth
factors for proceeding to mitosis and cytokinesis. If cells that have passed R2 are treated with
Rapamycin, they will have committed to replicating the genome with mTORC1 inhibited –
indicating a shortage of the raw materials to finish the job. Under these conditions, an apparent
default apoptotic pathway is activated when mTORC1 is suppressed (Saqcena et al., 2015). In
this report, we have identified conditions in cancer cells that are resistant to the apoptotic effects
of Rapamycin. The resistance to Rapamycin occurs in cancer cells with loss-of-function
mutations to RB and CDKN2A. A key outcome of defects in these two tumor suppressor genes
is elevated expression of E2F family transcription factors, which apparently suppresses the
apoptotic pathway activated by Rapamycin (Fig. 2.4). The requirement of the CDKN2A mutation
is somewhat surprising in that p16Ink4A, encoded by CDKN2A, inhibits phosphorylation of pRb
by cyclin D-CDK 4/6 and thus the loss of p16INK4A is similar to the loss of pRb function in that
both prevent association between pRb and E2F family transcription factors (Witkiewicz et al.,
2011). However, CDKN2A also encodes p14ARF, which is expressed from an alternative reading
frame. While p14ARF is known mostly for preventing the degradation of p53 (Agrawal et al.,
2006), it also directly binds and suppresses E2F activity (Mason et al., 2002). Thus, the loss of
both wild type RB and CDKN2A genes is apparently required for elevated expression of E2F
family transcription factors.
Much progress has been made in the field of precision medicine whereby therapeutic
approaches are based on the specific signals that are dysregulated in a given tumor after
determining the genetic changes in the tumor cells (Ilagan and Manning, 2016). It has been
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suggested that the most dysregulated signals in human cancer are those that lead to elevated
mTORC1 (Blagosklonny, 2011; Ward and Thompson, 2012). Therefore, there have been many
attempts at targeting mTORC1 and the signals that target mTORC1 (Ilagan and Manning, 2016).
Targeting mTORC1 in cancers with defective TGF-β signals is an especially attractive strategy
because in the presence of TGF-β signals, Rapamycin induces late G1 cell cycle arrest; but in the
absence of TGF-β signals, cancer cells progress into S-phase where Rapamycin induces apoptosis
rather than G1 arrest (Foster and Gadir, 2008; Gadir et al., 2008; Le Gendre et al., 2013). In this
thesis, we have determined that cancer cells with defective RB and CDKN2A are resistant to the
apoptotic effect of Rapamycin. This information could be valuable for designing therapeutic
strategies that target mTORC1.
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CHAPTER FOUR: CONCLUSION AND FUTURE DIRECTIONS
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In this study, although we have revealed a mechanism which causes cancer cells to
become resistant to the apoptotic effect of Rapamycin, several gaps need to be filled. In Fig 2.2,
we showed that in the absence of wild type RB (i.e., in cell lines MDA-MB-468 and BT-549),
cells are sensitive to the cytotoxic effect of Rapamycin in serum-free media, and this is because
of the presence of wild type CDKN2A which is inhibiting the transcriptional activity of E2F. It
would be interesting to check the cytotoxic effect of Rapamycin in these cell lines upon
knockdown of wild type CDKN2A in the presence of mutant RB.
Literature studies revealed that in many cancer cells mTOR inhibition by Rapamycin
activates a negative feedback loop which upregulates AKT activity (O'Reilly et al., 2006; Sun et
al., 2005). Therefore, hyperactive AKT can provide survival cues to the cancer cells that help
them to progress through the cell cycle and could be one of the reasons for bypassing the cytotoxic
effect of Rapamycin. The canonical mechanism of AKT activation occurs via phosphorylation at
S473 and T308 sites by PI3K leading to cell proliferation and survival (Manning and Toker, 2017).
Hence it is crucial to probe for AKT phosphorylation levels in the Rapamycin resistant cell lines
which could shed more light to the Rapamycin resistant mechanism.
Recent studies claim that hyperactivation of AKT by cyclin A-CDK2 complex via
phosphorylation at S477 and T479 sites is required for cancer cells to survive (Liu et al., 2014).
Since DU-145 and NCI-H2228 cell lines are both RB and CDKN2A mutant, and the TGF-β
signaling pathway is blocked as treatment condition, the cyclins and their corresponding CDK
partners, such as cyclin E-CDK2 and cyclin A-CDK2 complexes might be activated. These kinase
complexes, functional during G1 to S phase transition and during S phase of the cell cycle
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(Malumbres, 2014), may be responsible for rescuing the cancer cells from the apoptotic effect of
Rapamycin and causing cell survival. To verify if cell survival is occurring via cyclin E-CDK2
and cyclin A-CDK2 upregulation, it would be essential to probe for the protein levels of these
cyclin complexes and investigate in detail their role in suppressing Rapamycin mediated
apoptosis.
Since this study suggest a significant role of E2F transcription factor in conferring
resistance to Rapamycin treatment, it is essential to further explore the function of E2F family
members in cell cycle regulation and cell proliferation. For example, E2F7 and E2F8 which are
critical to repress the transcriptional activity of other E2F members including E2F1, E2F2 and
E2F3, have been shown to enhance cancer progression when knocked down in liver or skin of
mice (Kent et al., 2016; Thurlings et al., 2017). Loss of E2F7 and E2F8 also have impact on
elevating the activity of other E2F members necessary for cell cycle progression (Thurlings et al.,
2017). Moreover, E2F7 and E2F8 that have been found to be involved in preventing DNA
synthesis during DNA damage- their loss or dysregulated function can induce apoptotic cell death
(Thurlings et al., 2017; Zalmas et al., 2008). Therefore, thorough investigation on the activity of
E2F family members in context of cancer progression is indispensable for improving targeted
cancer therapy.
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CHAPTER FIVE: MATERIALS AND METHODS
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Cells and cell culture conditions
MDA-MB-231, MCF-7, MDA-MB-468, BT-549, DU145 and NCI-H2228 human cancer
cell lines used in this study were obtained from the American Type Culture Collection (ATCC).
MDA-MB-231, MCF-7, MDA-MB-468, BT-549 and DU145 cell lines were cultured in
Dulbecco’s Modified Eagle’s Media (DMEM) (Sigma D6429) supplemented with 10% Fetal
Bovine Serum (FBS) (Sigma 12306C), 1% penicillin-streptomycin (Invitrogen) and maintained at
37º C in a humidified 5% CO2 incubator. NCI-H2228 cell line was cultured in Roswell Park
Memorial Institute media (RPMI-1640) (Sigma R8758) supplemented with 10% FBS, 1%
penicillin-streptomycin and maintained at 37º C in a humidified 5% CO2 incubator.
Antibodies and Reagents
Antibodies against pRb (9309), phospho-4E-BP1 (9451), 4E-BP1 (9452), cleaved polyADP-ribose polymerase (PARP) (9541), GAPDH (2118) and Actin (3700) were obtained from
Cell Signaling Technology; anti-mouse (SA00001-1) and anti-rabbit (SA00001-2) HRPconjugated secondary antibodies were obtained from Proteintech. Negative control scrambled
siRNA (D-001206) and siRNA targeted against human pRb (L-003296-02-0005) were obtained
from Dharmacon. Plasmid with hemagglutinin (HA) tagged Rb and HA tagged empty vector were
obtained from Genewiz. Lipofectamine RNAiMax (13778) used for siRNA transfection and
Lipofectamine 3000 transfection kit (L3000015) used for plasmid transfection, and XTT (X6493)
were obtained from ThermoFisher. Rapamycin (R-5000) was obtained from LC Laboratories. The
E2F inhibitor HLM006474 (324461) was obtained from Sigma.
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Cell viability assays
Cell viability for Figure 1A was determined by trypan blue exclusion assay. After 24 h
of treatment, cells were harvested, washed, and stained with trypan blue dye at a concentration of
0.4% (w/v). After 20 min incubation at room temperature, trypan blue uptake (by dead cells) was
scored by a hemocytometer. For all other cell viability measurements, (2,3-bis-(2-methoxy-4nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide) (XTT) reduction assay was used. In brief, 5
X 104 cells / 500 μl well were seeded into 24-well plates in triplicate. After 24 h, cells were given
treatment medium with or without drug as indicated and incubated at 37˚C and 5% CO2. After a
24 h incubation period, cells were treated with 125 μl of XTT for 2 h. Plates were then read at 450
nm wavelength by a spectrophotometer (Molecular devices, SpectraMax i3). After subtracting
blank well absorbance, the absorbance of vehicle treated cells was set to 100%, and the relative
absorbance of cells treated with drug (as indicated) was reported as % viable cells.
Transient transfections
Cells were plated in 6-well plates in medium supplemented with 10% FBS and 1%
penicillin-streptomycin. Next day, cells were transferred to serum-free and antibiotic-free media
and transfected with either plasmid (10 µg/ml) in Lipofectamine 3000 (Thermofisher) or siRNAs
(100nM) in Lipofectamine RNAiMax. After 5 h, the transfection media and reagents were replaced
with fresh media containing 10% FBS and the cells were incubated for additional 48 h (plasmid)
or 72 h (siRNA).
Immunoblot Analysis
Proteins from the treated cell samples were extracted after lysis with M-PER buffer
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(ThermoScientific 78501). 20 µg of protein samples were subjected to SDS- PAGE separating
gels. Electrophoresed proteins were transferred onto nitrocellulose membrane. After transfer, the
membranes were blocked in an isotonic solution containing 5% non-fat dry milk and incubated
overnight with primary antibodies as indicated in the text. The membranes were then washed and
incubated with secondary antibodies (anti-mouse or anti-rabbit depending on the origin of the
primary antibodies) for 1 h at room temperature and protein levels were visualized using ECL
system (Kindle Biosciences 1002).
Statistical Analysis
Statistical significance was analyzed using GraphPad Prism 8 software. Comparisons
between two sets of samples were carried out by unpaired Student’s t-tests. Data were plotted as
the mean with standard deviation of three individual experiments performed in triplicates. The pvalues are as follow: *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001. Not significance
(ns) means p > 0.05.
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